X-154030930-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BS2_Supporting
The NM_001110792.2(MECP2):c.934G>A(p.Val312Ile) variant causes a missense change. The variant allele was found at a frequency of 0.00000496 in 1,210,609 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 3 hemizygotes in GnomAD. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0000089 ( 0 hom., 1 hem., cov: 23)
Exomes 𝑓: 0.0000046 ( 0 hom. 2 hem. )
Consequence
MECP2
NM_001110792.2 missense
NM_001110792.2 missense
Scores
4
2
5
Clinical Significance
Conservation
PhyloP100: 5.42
Genes affected
MECP2 (HGNC:6990): (methyl-CpG binding protein 2) DNA methylation is the major modification of eukaryotic genomes and plays an essential role in mammalian development. Human proteins MECP2, MBD1, MBD2, MBD3, and MBD4 comprise a family of nuclear proteins related by the presence in each of a methyl-CpG binding domain (MBD). Each of these proteins, with the exception of MBD3, is capable of binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can also repress transcription from methylated gene promoters. In contrast to other MBD family members, MECP2 is X-linked and subject to X inactivation. MECP2 is dispensible in stem cells, but is essential for embryonic development. MECP2 gene mutations are the cause of most cases of Rett syndrome, a progressive neurologic developmental disorder and one of the most common causes of cognitive disability in females. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -1 ACMG points.
BS2
High Hemizygotes in GnomAdExome4 at 2 XL geneVariant has number of hemizygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MECP2 | NM_001110792.2 | c.934G>A | p.Val312Ile | missense_variant | 3/3 | ENST00000453960.7 | NP_001104262.1 | |
MECP2 | NM_004992.4 | c.898G>A | p.Val300Ile | missense_variant | 4/4 | ENST00000303391.11 | NP_004983.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MECP2 | ENST00000453960.7 | c.934G>A | p.Val312Ile | missense_variant | 3/3 | 1 | NM_001110792.2 | ENSP00000395535.2 | ||
MECP2 | ENST00000303391.11 | c.898G>A | p.Val300Ile | missense_variant | 4/4 | 1 | NM_004992.4 | ENSP00000301948.6 |
Frequencies
GnomAD3 genomes AF: 0.00000890 AC: 1AN: 112383Hom.: 0 Cov.: 23 AF XY: 0.0000290 AC XY: 1AN XY: 34521
GnomAD3 genomes
AF:
AC:
1
AN:
112383
Hom.:
Cov.:
23
AF XY:
AC XY:
1
AN XY:
34521
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000455 AC: 5AN: 1098226Hom.: 0 Cov.: 35 AF XY: 0.00000550 AC XY: 2AN XY: 363582
GnomAD4 exome
AF:
AC:
5
AN:
1098226
Hom.:
Cov.:
35
AF XY:
AC XY:
2
AN XY:
363582
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000890 AC: 1AN: 112383Hom.: 0 Cov.: 23 AF XY: 0.0000290 AC XY: 1AN XY: 34521
GnomAD4 genome
AF:
AC:
1
AN:
112383
Hom.:
Cov.:
23
AF XY:
AC XY:
1
AN XY:
34521
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:6
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Rett syndrome Uncertain:4
Uncertain significance, no assertion criteria provided | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 17, 2015 | - - |
Uncertain significance, no assertion criteria provided | curation | RettBASE | Sep 27, 2012 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Nov 15, 2019 | - - |
Uncertain significance, criteria provided, single submitter | curation | Centre for Population Genomics, CPG | Jan 10, 2024 | This variant has been collected from RettBASE and curated to current modified ACMG/AMP criteria. Based on the classification scheme defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders Specifications to the ACMG/AMP Variant Interpretation Guidelines VCEP 3.0, this variant is classified as a variant of uncertain significance. At least the following criteria are met: Occurs in the well-characterized Transcriptional repression domain (TRD) of MECP2 (PM1). This variant has been identified as a de novo occurrence in an individual with Rett syndrome without confirmation of paternity and maternity (PM6). PMID: 11462237 This variant is absent from gnomAD (PM2_Supporting). - |
Syndromic X-linked intellectual disability Lubs type Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Sep 07, 2021 | A hemizygous missense variation in exon 3 of the MECP2 gene (chrX:g.154030930C>T; Depth: 45x) that results in the amino acid substitution of Isoleucine for Valine at codon 312 (p.Val312Ile; ENST00000453960.7) was detected. The p.Val312Ile variant has not been reported in the 1000 genomes database and has a minor allele frequency of 0.0009% in the gnomAD databases. The in silico predictions of the variant are possibly damaging by PolyPhen-2 (HumDiv) and damaging by LRT and MutationTaster2. The reference codon is conserved across species. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 27, 2018 | The p.V300I variant (also known as c.898G>A), located in coding exon 3 of the MECP2 gene, results from a G to A substitution at nucleotide position 898. The valine at codon 300 is replaced by isoleucine, an amino acid with highly similar properties. This variant has been reported as de novo in a female with classical Rett syndrome (Nicolao P et al. Hum. Mutat., 2001 Aug;18:132-40), as well as in a female with nonspecific intellectual disability and in her unaffected mother (Zvereff V et al. Brain Dev., 2012 Oct;34:750-5). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Autism, susceptibility to, X-linked 3 Uncertain:1
Uncertain significance, no assertion criteria provided | curation | RettBASE | Sep 27, 2012 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D
Sift4G
Benign
T
Vest4
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at